2cureX - IndiTreat market launch imminent
2021-06-04 10:00:00
Redeye returns with an updated take on 2cureX following TICC trial result publication. Following this successful proof-of-concept, the company is now ready for IndiTreat commercialization in metastatic colorectal cancer. Reassessing its commercial outlook and our financial estimates, we have updated our fair value range.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/